We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
+30.67%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$322M
AUM Growth
+$14.6M
Cap. Flow
-$53.2M
Cap. Flow %
-16.53%
Top 10 Hldgs %
94.68%
Holding
23
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$53.2M
2
VTGN icon
VistaGen Therapeutics
VTGN
+$23.8K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
1
Protagonist Therapeutics
PTGX
$9.8B
$67.6M 21%
2,449,183
– –
LEGN icon
2
Legend Biotech
LEGN
$3.93B
$56.2M 17.46%
814,586
-814,587
-50% -$53.2M
CVRX icon
3
CVRx
CVRX
$78.3M
$54M 16.76%
3,495,575
– –
MGTX icon
4
MeiraGTx Holdings
MGTX
$1.17B
$44.6M 13.86%
6,641,064
– –
XNCR icon
5
Xencor
XNCR
$1.71B
$18.7M 5.8%
748,062
– –
FUSN
6
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$17.1M 5.32%
3,670,516
– –
FATE icon
7
Fate Therapeutics
FATE
$294M
$16.1M 4.99%
3,379,064
– –
PRCT icon
8
Procept Biorobotics
PRCT
$1.26B
$12.7M 3.93%
357,939
– –
PNT
9
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$9.06M 2.81%
1,000,000
– –
ARWR icon
10
Arrowhead Research
ARWR
$12.1B
$8.83M 2.74%
247,598
– –
NNOX icon
11
Nano X Imaging
NNOX
$73.2M
$4.92M 1.53%
317,704
– –
VOR icon
12
Vor Biopharma
VOR
$1.38B
$3.32M 1.03%
53,733
– –
ALDX icon
13
Aldeyra Therapeutics
ALDX
$86.9M
$3.31M 1.03%
394,834
– –
HLTH
14
DELISTED
Cue Health Inc. Common Stock
HLTH
$2.05M 0.64%
5,548,864
– –
ACET icon
15
Adicet Bio
ACET
$77.3M
$1.77M 0.55%
45,559
– –
PHGE icon
16
BiomX
PHGE
$1.67M
$768K 0.24%
11,228
– –
SLGC
17
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$649K 0.2%
281,052
– –
CLSD
18
DELISTED
Clearside Biomedical
CLSD
$190K 0.06%
11,309
– –
APLM icon
19
Apollomics
APLM
$38.1M
$75.9K 0.02%
133
– –
SENS icon
20
Senseonics Holdings Inc
SENS
$409M
$41.7K 0.01%
2,731
– –
TCON
21
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$24.4K 0.01%
4,200
– –
GYRE icon
22
Gyre Therapeutics
GYRE
$693M
$23.5K 0.01%
4,463
– –
VTGN icon
23
VistaGen Therapeutics
VTGN
$11.8M
– –
-6,350
Closed -$23.8K

Similar funds

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
UM
Ulysses Management New York $802M AUM 5.35% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Johnson & Johnson's Q2 2023 Portfolio in Review

As of Q2 2023, Johnson & Johnson held 23 positions worth $322M, up 4.8% from $307M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Johnson & Johnson withdrew a net $53.2M in Q2 2023, closing 1 position and reducing 1 holding. Its most notable exit was VistaGen Therapeutics, an estimated $23.8K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Johnson & Johnson's biggest Q2 2023 reduction was Legend Biotech, cutting an estimated $53.2M.
  • Johnson & Johnson fully exited VistaGen Therapeutics in Q2 2023, selling an estimated $23.8K.
  • Johnson & Johnson's ten largest holdings make up 95% of its $322M portfolio in Q2 2023.
  • Johnson & Johnson opened 0 new positions and closed 1 in Q2 2023.
  • Johnson & Johnson's portfolio value rose 4.8% quarter-over-quarter to $322M.

Based on Johnson & Johnson's 13F filing for Q2 2023, filed 2 Aug 2023.